跳转至内容
Merck
CN

F0175000

氟胞嘧啶

European Pharmacopoeia (EP) Reference Standard

别名:

5-氟胞嘧啶, 4-氨基-5-氟-2(1H)-嘧啶酮, 氟胞嘧啶

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C4H4FN3O
化学文摘社编号:
分子量:
129.09
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
127285
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氟胞嘧啶, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)

SMILES string

NC1=NC(=O)NC=C1F

InChI key

XRECTZIEBJDKEO-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

flucytosine

manufacturer/tradename

EDQM

mp

298-300 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

具有抗真菌活性的核苷类似物。 5-FC由胞嘧啶脱氨基酶脱氨,可产生5-氟尿嘧啶,导致RNA密码错编。 5-氟尿嘧啶可抑制DNA和RNA的合成,干扰核糖体蛋白质合成。

Application

Flucytosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazard

signalword

Warning

hcodes

pcodes

Hazard Classifications

Repr. 2

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

R Patel
Mayo Clinic proceedings, 73(12), 1205-1225 (1998-12-30)
Traditionally, amphotericin B has been the cornerstone of antifungal treatment. Toxicity, however, is a major dose-limiting factor of amphotericin B deoxycholate. Nevertheless, it continues to have a major role in the treatment of deep-seated mycotic infections. Recently, less nephrotic lipid
A Polak
Annales de biologie clinique, 45(6), 669-672 (1987-01-01)
The antimycotic and pharmacological properties of 5-fluorocytosine are presented. Especially the aspect of good gastrointestinal absorption, elimination by the kidney, unwanted side effects and appearance of primary and secondary resistance are discussed. The indication of 5 FC monotherapy or combination
Nese Karaaslan Biyikli et al.
Pediatric nephrology (Berlin, Germany), 19(7), 801-804 (2004-06-03)
Bilateral fungal obstruction of the renal collecting system is rare in infancy. Treatment options include medical or surgical procedures. Reports of successful medical treatment with liposomal amphotericin B have been published but the duration of treatment is controversial. We report
B Gerson
Clinics in laboratory medicine, 7(3), 541-544 (1987-09-01)
Monitoring of flucytosine (5-FC) concentration in serum is of great importance. It may be anticipated that demand for this service will increase in the near future, because this drug is used in situations involving immunocompromised patients, including those afflicted with
Angela Loyse et al.
The Journal of antimicrobial chemotherapy, 68(11), 2435-2444 (2013-06-22)
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持